Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

October 09, 2025

MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a poster presentation at the American Heart Association Scientific Sessions 2025, to be held November 7-10th in New Orleans, Louisiana. Data to be presented describe the efficacy, safety, and tolerability of self-administered etripamil by patients with episodes of paroxysmal supraventricular tachycardia.

AHA 2025 Presentation Details:

Poster Presentation Title:	Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials
Presenter:	James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time:	Monday, November 10, 2025, 10:30 – 11:30 AM CST

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.

Investor Relations

Kevin Gardner, kgardner@lifesciadvisors.com

Source: Milestone Pharmaceuticals Inc.